.Jarushka Naidoo discusses #EGFR -M+ NSCLC therapeutics highlighting PACC mutations. FLAURA2 ctDNA confirms prognostic utility not predictive: NOT informing treatment selection. VTE risks with MARIPOSA1 schedule concerning for deliverability. Superb overview 👏👏 #BTOG24

Some advances for our BRAFV600E NSCLC patients… two standards in 2024 with Dabrafenib + Trametinib and Encorafenib + Binimetinib
review to read… npj Journals
rdcu.be/dE0vT

30 Posts Not To Miss From AACR 24 !
Dr. Kimryn Rathmell Lynn M. Schuchter, MD, FASCO @ASCO Vivek Subbiah, MD Dr. Patrick Hwu Wafik S. El-Deiry, MD, PhD, FACP Chendi Li d.planchard Harmony Saunders Paolo Tarantino AACR_CEO Jakob Nikolas Kather Nicholas Huntington Pashtoon Kasi MD, MS K Lukasik Christine Lovly, MD, PhD Ivy Riano, M.D. #OncoDaily

oncodaily.com/48590.html

During #ELCC24 , Dr. Natalia Valdiviezo presented FLAURA2 post-progression outcomes data, as well as data from a second interim overall survival analysis from the trial. Read a recap in #ILCN : bit.ly/49uLQh5 #LCSM

It's great to see Gustave Roussy on the water in Brittany in the Golf du Morbihan, one of the most beautiful places in France! And the land of real sailors at the port of La Trinité... Gustave Roussy Gustave Roussy Alumni

FLAURA2 exploratory analysis discussion by Marina Garassino at #AACR24 :
🔺dynamic ctDNA analysis not useful for clinical decisions
🔹baseline detection of EGFRm is prognostic and may select for a higher degree of clinical benefit from Osi+CT
AACR

Baseline (before tx) ctDNA level in #EGFR metastatic #NSCLC in FLAURA2 trial (osimertinib vs. osi + chemo) suggests - combo more beneficial when ctDNA detected. Potential strategy for tx adaptation? What about non-shedding tumors? #PasiJanne Dana-Farber #AACR24 EGFR Resisters

FLAURA2: On-treatment plasma EGFRm clearance prognostic but not predictive benefit with osimertinib + ChemoT vs Osi alone by P.Jänne at #AACR24 Gustave Roussy Dana Farber's EGFR-Mutant Lung Cancer Center Dana-Farber News EGFR Resisters

FLAURA2- Baseline detection of ctDNA may identify a subgroup of pts who derive most benefit from addition of chemoT to osimertinib as first line trtt for EGFRmut NSCLC by P.Jänne at #AACR24 EGFR Resisters Dana Farber's EGFR-Mutant Lung Cancer Center Gustave Roussy Dana-Farber News

Don't miss Tuesday's presentation by Pasi. Jänne on ctDNA in the FLAURA2 study ... at #AACR24 EGFR Resisters

Follow the post progression outcomes update of the controversial FLAURA2 Trial from the #ELCC24 conference. Key commentary from Jarushka Naidoo Balazs Halmos Stephen V Liu, MD d.planchard #lcsm
👉beta.kolpulse.com/public/1409290…

This may cover a need in this population with few therapeutic options.

Results from DESTINY-Lung01: trastuzumab deruxtecan in #HER2 overexpressing cohort now The Lancet Oncology. T-DXd (HER2-ADC) 5.4mg/kg showed RR 34%, mPFS 6.7m with 5% ILD in HER2 overexpressing NSCLC. Activity, though not as much as HER2 mutant NSCLC.

thelancet.com/journals/lanon…

Dr. Natalia Valdiviezo presents post-progression outcomes including OS from FLAURA-2 at #ELCC24 . Adding platinum-based chemotherapy to first-line osimertinib for #EGFR NSCLC improved PFS (HR 0.62) but what is the impact on long-term outcomes?

See you next year in Paris! It's shaping up to be a great ELCC25 meeting... #ELCC24 ESMO - Eur. Oncology IASLC

Great to see the results of FLAURA2, which confirm our hopes for our patients: to increase their PFS, PFS2 and survival (still immature but more than promising) while limiting toxicities (High demand from our often young and active patients)... #ELCC24 ESMO - Eur. Oncology IASLC

FLAURA2 interim OS analysis: trend towards an OS benefit (HR 0.75; 95% CI 0.57, 0.97; p=0.0280) for osimertinib + platinum-pemetrexed chemotherapy versus osimertinib alone. #ELCC24 OncoAlert

#ELCC24
Post progression outcomes in FLAURA2 (Ph III Osi+chemo v Osi):
- interim OS HR 0.75 p=0.028, trend (41% maturity)
- benefit in TTST/TTFT (time to next therapy)

Are these ‘relevant’ endpoints? Further data needed to establish as a new SOC #ESMOambassadors ⁦ESMO - Eur. Oncology⁩

With more follow-up, the results confirm the benefit of the combination osi+chemoT on survival and PFS2 reinforces the significant benefit on PFS. Results still immature on survival... can't wait to see the ctDNA data to be presented at the AACR... #ELCC24 ESMO - Eur. Oncology IASLC

A fine review of the data and usefulness of MRD in clinical practice for both doctors and patients by Jordi Remon Gustave Roussy ! Predictive vs. prognostic? More work to do... #ELCC24 ESMO - Eur. Oncology IASLC